Biological features of hepatitis B virus strains associated with fulminant hepatitis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386(10003), 1546–1555 (2015).
  MedlineGoogle Scholar
• 2. GBD 2013 Mortality Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963), 117–171 (2015).
  MedlineGoogle Scholar
• 3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral. Hepat. 11(2), 97–107 (2004).
  Medline CASGoogle Scholar
• 4. WHO Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. World Health Organization, Geneva, Switzerland (2015). https://apps.who.int/iris/bitstream/handle/10665/154590/9789241549059_eng.pdf
  Google Scholar
• 5. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin. Gastroenterol. Hepatol. 4(9), 1076–1081 (2006).
  Medline CASGoogle Scholar
• 6. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog. Liver. Dis. 3, 282–298 (1970).
  Medline CASGoogle Scholar
• 7. Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver. Transpl. 14(2), S67–79 (2008).
  MedlineGoogle Scholar
• 8. Polson J, Lee WM. American association for the study of liver disease. AASLD position paper: the management of acute liver failure. Hepatology 41(5), 1179–1197 (2005).
  MedlineGoogle Scholar
• 9. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 376(9736), 190–201 (2010).
  MedlineGoogle Scholar
• 10. Acharya SK, Panda SK, Saxena A, Dattagupta S. Acute hepatic failure in India: a prospective from the East. J. Gastroenterol. Hepatol. 15(5), 473–479 (2000).
  Medline CASGoogle Scholar
• 11. Acharya SK, Batra Y, Hazari S, Choudhury V, Panda SK, Dattagupta S. Etiopathogenesis of acute hepatic failure: Eastern versus Western countries. J. Gastroenterol. Hepatol. 17(3), S268–S273 (2002).
  MedlineGoogle Scholar
• 12. Ostapowicz G, Lee WM. Acute hepatic failure: a western perspective. J. Gastroenterol. Hepatol. 15(5), 480–488 (2000).
  Medline CASGoogle Scholar
• 13. Sheil AG, McCaughan GW, Thompson JF, Dorney SF, Stephen MS, Bookallil MJ. The first five years' clinical experience of the Australian National Liver Transplantation Unit. Med. J. Aust. 156(1), 9–16 (1992).
  Medline CASGoogle Scholar
• 14. Escorsell A, Mas A, de la Mata M the Spanish Group for the Study of Acute Liver Failure. Acute liver failure in Spain: analysis of 267 cases. Liver. Transpl. 13(10), 1389–1395 (2007).
  MedlineGoogle Scholar
• 15. European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J. Hepatol. 66(5), 1047–1081 (2017).
  MedlineGoogle Scholar
• 16. Du WJ, Liu L, Sun C, Yu JH, Xiao D, Li Q. Prodromal fever indicates a high risk of liver failure in acute hepatitis B. Int. J. Infect. Dis. 57, 98–103 (2017).
  MedlineGoogle Scholar
• 17. Mendizabal M, Tagliafichi V, Rubinstein F et al. Liver transplantation in adults with acute liver failure: outcomes from the Argentinean Transplant Registry. Ann. Hepatol. 18(2), 338–344 (2019).
  MedlineGoogle Scholar
• 18. Berk PD, Popper H. Fulminant hepatic failure. Am. J. Gastroenterol. 69(3pt2), 349–400 (1978).
  Medline CASGoogle Scholar
• 19. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J. Clin. Virol. 34(1), S1–S3 (2005).
  MedlineGoogle Scholar
• 20. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 373(9663), 582–592 (2009).
  Medline CASGoogle Scholar
• 21. Stravitz RT, Lee WM. Acute liver failure. Lancet 394(10201), 869–881 (2019).
  Medline CASGoogle Scholar
• 22. Reuben A, Koch DG, Lee WM the Acute Liver Failure Study Group. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study. Hepatology 52(6), 2065–2076 (2010).
  MedlineGoogle Scholar
• 23. Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin. Mol. Hepatol. 22(2), 219–237 (2016).
  MedlineGoogle Scholar
• 24. Elefsiniotis I, Vezali E, Vrachatis D et al. Post-partum reactivation of chronic hepatitis B virus infection among hepatitis B e-antigen-negative women. World. J. Gastroenterol. 21(4), 1261–1267 (2015).
  Medline CASGoogle Scholar
• 25. Kamitsukasa H, Iri M, Tanaka A et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J. Med. Virol. 87(4), 589–600 (2015).
  Medline CASGoogle Scholar
• 26. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin. Liver. Dis. 33(2), 167–177 (2013).
  Medline CASGoogle Scholar
• 27. Valaydon ZS, Locarnini SA. The virological aspects of hepatitis B. Best. Pract. Res. Clin. Gastroenterol. 31(3), 257–264 (2017).
  Medline CASGoogle Scholar
• 28. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38(5), 1075–1086 (2003).
  Medline CASGoogle Scholar
• 29. Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell. Microbiol. 10(1), 122–133 (2008).
  Medline CASGoogle Scholar
• 30. Ni Y, Lempp FA, Mehrle S et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146(4), 1070–1083 (2014).
  Medline CASGoogle Scholar
• 31. Caballero A, Tabernero D, Buti M, Rodriguez-Frias F. Hepatitis B virus: The challenge of an ancient viruswith multiple faces and a remarkable replication strategy. Antivir. Res. 158, 34–44 (2018).
  Medline CASGoogle Scholar
• 32. Vierling JM. The immunology of hepatitis B. Clin. Liver. Dis. 11(4), 727–759 (2007).
  MedlineGoogle Scholar
• 33. Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J. Exp. Med. 57(4), 231–236 (1987).
  Medline CASGoogle Scholar
• 34. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 93(9), 4398–4402 (1996).
  Medline CASGoogle Scholar
• 35. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J. Clin. Virol. 32(2), 102–112 (2005).
  Medline CASGoogle Scholar
• 36. Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus. Res. 127(2), 164–176 (2007). • Provides detailed overview of hepatitis B virus (HBV) genetic variability, including natural variability, which is the result of gradual evolution and variability that results from adaptation of the virus to different selective pressures.
  Medline CASGoogle Scholar
• 37. Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J. Gen. Virol. 69(pt10), 2575–2583 (1988).
  Medline CASGoogle Scholar
• 38. Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J. Hepatol. 64(1), S4–S16 (2016).
  Medline CASGoogle Scholar
• 39. Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J. Hepatol. 67(6), 1281–1297 (2017).
  MedlineGoogle Scholar
• 40. Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 57(3–4), 141–150 (2014).
  MedlineGoogle Scholar
• 41. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J. Gastroenterol. Hepatol. 26(1), 123–130 (2011).
  MedlineGoogle Scholar
• 42. Thuy PT, Alestig E, Liem NT, Hannoun C, Lindh M. Genotype X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam-genotypes B4 and C1 predominate. J. Med. Virol. 82(8), 1327–1333 (2010).
  MedlineGoogle Scholar
• 43. Olinger CM, Jutavijittum P, Hubschen JM et al. Possible new hepatitis B virus genotype, southeast Asia. Emerg. Infect. Dis. 14(11), 1777–1780 (2008).
  MedlineGoogle Scholar
• 44. Tatematsu K, Tanaka Y, Kurbanov F et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J. Virol. 83(20), 10538–10547 (2009).
  Medline CASGoogle Scholar
• 45. Liu M, Chan CW, McGilvray I, Ning Q, Levy GA. Fulminant viral hepatitis: molecular and cellular basis, and clinical implications. Expert. Rev. Mol. Med. 2001, 1–19 (2001).
  Medline CASGoogle Scholar
• 46. Jouanguy E. Human genetic basis of fulminant viral hepatitis. Hum. Genet. doi:10.1007/s00439-020-02166-y (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 47. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis resulting in enhanced viral replication. J. Clin. Invest. 98(10), 2268–2276 (1996).
  Medline CASGoogle Scholar
• 48. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J. Virol. 68(3), 1651–1659 (1994).
  Medline CASGoogle Scholar
• 49. Rivero M, Crespo J, Fabrega E et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J. Viral. Hepat. 9(2), 107–113 (2002).
  MedlineGoogle Scholar
• 50. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 3(5), 656–662 (1983).
  Medline CASGoogle Scholar
• 51. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral. Hepat. 9(1), 52–61 (2002).
  Medline CASGoogle Scholar
• 52. Kosaka Y, Takase K, Kojima M et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 100(4), 1087–1094 (1991).
  Medline CASGoogle Scholar
• 53. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N. Engl. J. Med. 324, 1705–1709 (1991).
  Medline CASGoogle Scholar
• 54. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N. Engl. J. Med. 324(24), 1699–1704 (1991).
  Medline CASGoogle Scholar
• 55. Sato S, Suzuki K, Akahane Y et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann. Intern. Med. 122(4), 241–249 (1995).
  Medline CASGoogle Scholar
• 56. Ozasa A, Tanaka Y, Orito E et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44(2), 326–334 (2006).
  Medline CASGoogle Scholar
• 57. Kusakabe A, Tanaka Y, Mochida S et al. Case–control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol. Res. 39(7), 648–656 (2009).
  Medline CASGoogle Scholar
• 58. Sugiyama M, Tanaka Y, Kurbanov F, Nakayama N, Mochida S, Mizokami M. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. Virology. 365(2), 285–291 (2007).
  Medline CASGoogle Scholar
• 59. Inoue J, Ueno Y, Kawamura K et al. Association between S21 substitution in the core protein of hepatitis B virus and fulminant hepatitis. J. Clin. Virol. 55(2), 147–152 (2012).
  Medline CASGoogle Scholar
• 60. Parekh S, Zoulim F, Ahn SH et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J. Virol. 77(12), 6601–6612 (2003).
  Medline CASGoogle Scholar
• 61. Chen IH, Huang CJ, Ting LP. Overlapping initiator and TATA box functions in the basal core promoter of hepatitis B virus. J. Virol. 69(6), 3647–3657 (1995).
  Medline CASGoogle Scholar
• 62. Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J. Virol. 73(2), 1239–1244 (1999).
  Medline CASGoogle Scholar
• 63. Tsai A, Kawai S, Kwei K et al. Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. Virology. 387(2), 364–372 (2009).
  Medline CASGoogle Scholar
• 64. Jammeh S, Tavner F, Watson R, Thomas HC, Karayiannis P. Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J. Gen. Virol. 89(pt4), 901–909 (2008).
  Medline CASGoogle Scholar
• 65. Hoshino T, Takagi H, Suzuki Y et al. Fatal fulminant hepatitis caused by infection with subgenotype A1 hepatitis B virus with C1766T/T1768A core promoter mutations. Clin. J. Gastroenterol. 9(3), 160–167 (2016).
  MedlineGoogle Scholar
• 66. Guidotti LG, Matzke B, Pasquinelli C, Shoenberger JM, Rogler CE, Chisari FV. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J. Virol. 70(10), 7056–7061 (1996).
  Medline CASGoogle Scholar
• 67. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schroder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J. Virol. 67(7), 3756–3762 (1993).
  Medline CASGoogle Scholar
• 68. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48(2), 335–352 (2008).
  MedlineGoogle Scholar
• 69. Chen MT, Billaud JN, Sallberg M et al. A function of the hepatitis B virus pre-core protein is to regulate the immune response to the core antigen. Proc. Natl. Acad. Sci. USA 101(41), 14913–14918 (2004).
  Medline CASGoogle Scholar
• 70. Chen M, Sallberg M, Hughes J et al. Immune tolerance split between hepatitis B virus pre-core and core proteins. J. Virol. 79(5), 3016–3027 (2005).
  Medline CASGoogle Scholar
• 71. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. USA 87(17), 6599–6603 (1990).
  Medline CASGoogle Scholar
• 72. Bocharov G, Ludewig B, Bertoletti A et al. Underwhelming the immune response: effect of slow virus growth on CD8+-T-lymphocyte responses. J. Virol. 78(5), 2247–2254 (2004).
  Medline CASGoogle Scholar
• 73. Inoue J, Ueno Y, Nagasaki F et al. Enhanced intracellular retention of a hepatitis B virus strain associated with fulminant hepatitis. Virology. 395(2), 202–209 (2009).
  Medline CASGoogle Scholar
• 74. Chisari FV. Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 99(7), 1472–1477 (1997).
  Medline CASGoogle Scholar
• 75. Ning B, Shih C. Nucleolar localization of human hepatitis B virus capsid protein. J. Virol. 78(24), 13653–13668 (2004).
  Medline CASGoogle Scholar
• 76. Inoue J, Ueno Y, Wakui Y et al. Enhanced replication of hepatitis B virus with frameshift in the precore region found in fulminant hepatitis patients. J. Infect. Dis. 204(7), 1017–1025 (2011).
  MedlineGoogle Scholar
• 77. Sendi H, Mehrab-Mohseni M, Shahraz S et al. CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. J. Clin. Virol. 46(3), 259–264 (2009).
  Medline CASGoogle Scholar
• 78. Sato N, Watanabe S, Miura K et al. Acute liver failure caused by the transmission of hepatitis B virus from the spouse after 38 years of marriage. Intern. Med. 58(20), 2963–2968 (2019).
  MedlineGoogle Scholar
• 79. Anastasiou OE, Widera M, Westhaus S et al. Clinical outcome and viral genome variability of hepatitis B virus-induced acute liver failure. Hepatology 69(3), 993–1003 (2019).
  Medline CASGoogle Scholar
• 80. Arankalle VA, Gandhi S, Lole KS, Chadha MS, Gupte GM, Lokhande MU. An outbreak of hepatitis B with high mortality in India: association with precore, basal core promoter mutants and improperly sterilized syringes. J. Viral. Hepat. 18(4), e20–e28 (2011).
  Medline CASGoogle Scholar
• 81. Khare S, Negi SS, Singh S et al. Genetic analysis of precore/core and partial pol genes in an unprecedented outbreak of fulminant hepatitis B in India. Epidemiol. Infect. 140(10), 1823–1829 (2012).
  Medline CASGoogle Scholar
• 82. Trinks J, Marciano S, Esposito I et al. The genetic variability of hepatitis B virus subgenotype F1b precore/core gene is related to the outcome of the acute infection. Virus. Res. 277, 197840 (2020).
  Medline CASGoogle Scholar
• 83. Nian X, Xu Z, Liu Y et al. Association between hepatitis B virus basal core promoter/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis. Hepatol. Int. 10(4), 606–615 (2016).
  MedlineGoogle Scholar
• 84. Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J. Hepatol. 61(2), 408–417 (2014). •• Gives detail explanation of the influence pre-S/S variability has on clinical outcome of HBV infection including development of fulminant hepatitis (FH).
  Medline CASGoogle Scholar
• 85. Fan YF, Lu CC, Chen WC et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 33(1), 277–286 (2001).
  Medline CASGoogle Scholar
• 86. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 130(4), 1153–1168 (2006).
  Medline CASGoogle Scholar
• 87. Chen CH, Hung CH, Lee CM et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 133(5), 1466–1474 (2007).
  Medline CASGoogle Scholar
• 88. Choi MS, Kim DY, Lee DH et al. Clinical significance of pre-S mutations in patients with genotype C hepatitis B virus infection. J. Viral. Hepat. 14(3), 161–168 (2007).
  Medline CASGoogle Scholar
• 89. Zhang D, Dong P, Zhang K et al. Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment. BMC. Microbiol. 12, 307 (2012).
  Medline CASGoogle Scholar
• 90. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc. Natl Acad. Sci. USA 88(3), 1059–1063 (1991).
  Medline CASGoogle Scholar
• 91. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 194(1), 137–148 (1993).
  Medline CASGoogle Scholar
• 92. Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World. J. Gastroenterol. 24(31), 3488–3499 (2018).
  Medline CASGoogle Scholar
• 93. Pollicino T, Zanetti AR, Cacciola I et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology 26(2), 495–499 (1997).
  Medline CASGoogle Scholar
• 94. Yuasa R, Takahashi K, Dien B-V et al. Properties of hepatitis B virus genome recovered from Vietnamese patients with fulminant hepatitis in comparison with those of acute hepatitis. J. Med. Virol. 61(1), 23–28 (2000).
  Medline CASGoogle Scholar
• 95. Ogunbosi B, Smuts H, Eley B, Korsman S, De Lacy R, Hardie DR. Fulminant hepatitis B virus (HBV) infection in an infant following mother-to-child transmission of an e-minus HBV mutant: Time to relook at HBV prophylaxis in South African infants. S. Afr. Med. J. 108(5), 389–392 (2018).
  Medline CASGoogle Scholar
• 96. Ando K, Moriyama T, Guidotti LG et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J. Exp. Med. 178(5), 1541–1554 (1993).
  Medline CASGoogle Scholar
• 97. Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology 34(2), 385–394 (2001).
  Medline CASGoogle Scholar
• 98. Mina T, Amini Bavil Olyaee S, Tacke F, Maes P, Van Ranst M, Pourkarim MR. Genomic diversity of hepatitis b virus infection associated with fulminant hepatitis B development. Hepat. Mon. 15(6), e29477 (2015). •• Provides detailed review on HBV genome diversities related to clinical outcome, particularly fulminant hepatitis.
  MedlineGoogle Scholar
• 99. Anastasiou OE, Theissen M, Verheyen J et al. Clinical and virological aspects of HBV reactivation: a focus on acute liver failure. Viruses 11(9), E863 (2019).
  Medline CASGoogle Scholar
• 100. Mina T, Amini-Bavil-Olyaee S, Shirvani-Dastgerdi E, Trovão NS, Van Ranst M, Pourkarim MR. 15 year fulminant hepatitis B follow-up in Belgium: viral evolution and signature of demographic change. Infect. Genet. Evol. 49, 221–225 (2017). • Gives insight in mutational patterns of different open reading frames of HBV isolates from FH cases reported during 15 years of follow-up.
  MedlineGoogle Scholar
• 101. Lazarevic I, Banko A, Miljanovic D, Cupic M. Immune-escape hepatitis B virus mutations associated with viral reactivation upon immunosuppression. Viruses. 11(9), E778 (2019).
  Medline CASGoogle Scholar
• 102. Lentz TB, Loeb DD. Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J. Virol. 85(22), 11916–11927 (2011).
  Medline CASGoogle Scholar
• 103. Summers J, Smith PM, Horwich AL. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64(6), 2819–2824 (1990).
  Medline CASGoogle Scholar
• 104. Pollicino T, Amaddeo G, Restuccia A et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology. 56(2), 434–443 (2012).
  Medline CASGoogle Scholar
• 105. Lenhoff RJ, Summers J. Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes. J. Virol. 68(9), 5706–5713 (1994).
  Medline CASGoogle Scholar
• 106. Lenhoff RJ, Luscombe CA, Summers J. Acute liver injury following infection with a cytopathic strain of duck hepatitis B virus. Hepatology 29(2), 563–571 (1999).
  Medline CASGoogle Scholar
• 107. Tanwar S, Dusheiko G. Is there any value to hepatitis B virus genotype analysis? Curr. Gastroenterol. Rep. 14(1), 37–46 (2012).
  MedlineGoogle Scholar
• 108. Livingston SE, Simonetti JP, Bulkow LR et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 133(5), 1452–1457 (2007).
  Medline CASGoogle Scholar
• 109. Wong GL, Chan HL, Yiu KK et al. Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment. Pharmacol. Ther. 37(5), 517–526 (2013).
  Medline CASGoogle Scholar
• 110. Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trépo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J. Virol. 67(9), 5402–5410 (1993).
  Medline CASGoogle Scholar
• 111. Tong S, Li J, Wands JR, Wen YM. Hepatitis B virus genetic variants: biological properties and clinical implications. Emerg. Microbes. Infect. 2(3), e10 (2013). • Discusses the impact of viral genotypes and mutations/deletions in the pre-core, core promoter, pre-S and S gene on the establishment of chronic infection, development of FH and liver cancer.
  Medline CASGoogle Scholar
• 112. Kato H, Orito E, Gish RG et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 35(4), 922–929 (2002).
  Medline CASGoogle Scholar
• 113. Kao JH. Molecular epidemiology of hepatitis B virus. Korean. J. Intern. Med. 26(3), 255–261 (2011).
  MedlineGoogle Scholar
• 114. Nagasaki F, Ueno Y, Niitsuma H et al. Analysis of the entire nucleotide sequence of hepatitis B causing consecutive cases of fatal fulminant hepatitis in Miyagi Prefecture Japan. J. Med. Virol. 80(6), 967–973 (2008).
  Medline CASGoogle Scholar
• 115. Karin K-L, Myhre E, Blackberg J. Clinical and serological variation between patients infected with different hepatitis B virus genotypes. J. Clin. Microbiol. 42(12), 5837–5841 (2004).
  MedlineGoogle Scholar
• 116. Garfein RS, Bower WA, Loney CM et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology. 40(4), 865–873 (2004).
  MedlineGoogle Scholar
• 117. Wai CT, Fontana RJ, Polson J et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J. Viral. Hepat. 12(2), 192–198 (2005).
  MedlineGoogle Scholar
• 118. Chook JB, Ngeow YF, Tee KK, Peh SC, Mohamed R. Novel genetic variants of hepatitis B virus in fulminant hepatitis. J. Pathog. 2017, 1231204 (2017). • Identifies six HBV variants that are highly predictive and specific for the identification of patients at risk for FH.
  MedlineGoogle Scholar
• 119. Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection – EASL Special Conference. J. Hepatol. 63(5), 1238–1253 (2015).
  MedlineGoogle Scholar
• 120. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67(2), 370–398 (2017).
  MedlineGoogle Scholar